Treatment of asymptomatic aortic valve stenosis : Watchful waiting or early intervention?

J Ledwoch1,2, H Thiele3,4

  • 1Medical Clinic II (Medical Clinic II, Department of Cardiology, Angiology, Intensive Care Medicine), University Heart Center Lübeck, Universitätsklinikum Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany.

Herz
|June 9, 2017
PubMed

Insights

Management of severe asymptomatic aortic stenosis (AS) is debated. Current guidelines suggest watchful waiting, but evidence for improved survival with early aortic valve replacement is limited, necessitating further research.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Clinical Trials

Background:

  • Severe asymptomatic aortic stenosis (AS) management remains controversial.
  • Current guidelines advocate a watchful waiting approach for most asymptomatic patients.
  • Prognostic data for asymptomatic AS is inconsistent, with some studies suggesting conservative management may increase risks.

Purpose of the Study:

  • To evaluate the optimal management strategy for severe asymptomatic aortic stenosis.
  • To address the conflicting evidence regarding conservative versus early intervention.
  • To highlight the need for high-quality evidence to guide treatment decisions.

Main Methods:

  • Review of existing literature on asymptomatic severe AS.
  • Analysis of nonrandomized studies comparing early aortic valve replacement with watchful waiting.
  • Identification of methodological limitations in current research.

Main Results:

  • Some nonrandomized studies suggest improved survival with early aortic valve replacement in asymptomatic patients.
  • Significant methodological limitations exist in current comparative studies.
  • A clear recommendation for treatment options cannot be made based on available data.

Conclusions:

  • The optimal management strategy for severe asymptomatic aortic stenosis requires further investigation.
  • Randomized controlled trials are essential to provide robust evidence for treatment decisions.
  • Current evidence is insufficient to definitively support early intervention over watchful waiting.

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
518
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
376
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
403
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
898
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
848